Clinical Trial Update: Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011) [Phase 2]

View source ↗

Summary

Phase 2 trial update for islatravir with doravirine and lamivudine in HIV-1 infection completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Doravirine (doravirine)
• Islatravir (Islatravir)
• Lamivudine (lamivudine)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV-1 Infection | Phase 2 | Status: COMPLETED | Results posted: 2022-04-27